Whole animal HTS of small molecules for antifungal compounds

Expert Opinion on Drug Discovery

Volumn 11, Issue 2, 2016, Pages 177-184

  Muhammed, Maged ^a,b   Arvanitis, Marios ^c   Mylonakis, Eleftherios ^a,b  

^a RHODE ISLAND HOSPITAL   (United States)

^b BROWN UNIVERSITY   (United States)

^c BOSTON MEDICAL CENTER   (United States)

Author keywords

Antifungal agents; Caenorhabditis elegans; Candida albicans; Drosophila melanogaster; drug discovery; high throughput screen

Indexed keywords

ANTIFUNGAL AGENT;

CAENORHABDITIS ELEGANS; CANDIDIASIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG SCREENING; DRUG SOLUBILITY; HIGH THROUGHPUT SCREENING; HOST PATHOGEN INTERACTION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TOXICITY TESTING; ANIMAL; ANTIFUNGAL RESISTANCE; CHEMISTRY; DRUG DESIGN; DRUG DEVELOPMENT; HUMAN; MICROBIOLOGY; MYCOSES; PROCEDURES; SOLUBILITY;

ANIMALS; ANTIFUNGAL AGENTS; CAENORHABDITIS ELEGANS; DRUG DESIGN; DRUG DISCOVERY; DRUG RESISTANCE, FUNGAL; HIGH-THROUGHPUT SCREENING ASSAYS; HOST-PATHOGEN INTERACTIONS; HUMANS; MYCOSES; SOLUBILITY;

EID: 84957432755     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2016.1122591     Document Type: Review

References (80)

1. Antachopoulos C. Invasive fungal infections in congenital immunodeficiencies. Clin Microbiol Infect. 2010; 16 (9): 1335-1342.
2. Edmond MB, Wallace SE, McClish DK., et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis. 1999; 29 (2): 239-244.
3. Loeffler J, Stevens DA. Antifungal drug resistance. Clin Infect Dis. 2003; 36 (Suppl 1): S31-41.
4. Macphail GL, Taylor GD, Buchanan-Chell M., et al. Epidemiology, treatment and outcome of candidemia: a five-year review at three Canadian hospitals. Mycoses. 2002; 45 (5-6): 141-145.
5. Miller LG, Hajjeh RA, Edwards JE Jr. Estimating the cost of nosocomial candidemia in the United States. Clin Infect Dis. 2001; 32 (7): 1110.
6. Pappas PG, Kauffman CA, Andes D., et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009; 48 (5): 503-535.
7. Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America. Crit Rev Microbiol. 2010; 36 (1): 1-53.
8. Rentz AM, Halpern MT, Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis. 1998; 27 (4): 781-788.
9. Richardson M, Lass-Florl C. Changing epidemiology of systemic fungal infections. Clin Microbiol Infect. 2008; 14 (Suppl 4): 5-24.
10. Neoh CF, Slavin M, Chen SC., et al. Echinocandins in the treatment of candidaemia and invasive candidiasis: clinical and economic perspectives. Int J Antimicrob Agents. 2014; 43 (3): 207-214.
11. Magill SS, Edwards JR, Bamberg W., et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014; 370 (13): 1198-1208.
12. Hopkins AL, Bickerton GR. Drug discovery: know your chemical space. Nat Chem Biol. 2010; 6 (7): 482-483.
13. Segalat L. Drug discovery: here comes the worm. ACS Chem Biol. 2006; 1 (5): 277-278.
14. Moy TI, Conery AL, Larkins-Ford J., et al. High-throughput screen for novel antimicrobials using a whole animal infection model. ACS Chem Biol. 2009; 4 (7): 527-533.
15. ORourke EJ, Conery AL, Moy TI. Whole-animal high-throughput screens: the C. Elegans model. Methods Mol Biol. 2009; 486: 57-75.
16. Pukkila-Worley R, Holson E, Wagner F., et al. Antifungal drug discovery through the study of invertebrate model hosts. Curr Med Chem. 2009; 16 (13): 1588-1595.
17. Pukkila-Worley R, Mylonakis E. From the outside in and the inside out: antifungal immune responses in Caenorhabditis elegans. Virulence. 2010; 1 (3): 111-112.
18. Apidianakis Y, Rahme LG, Heitman J., et al. Challenge of Drosophila melanogaster with Cryptococcus neoformans and role of the innate immune response. Eukaryot Cell. 2004; 3 (2): 413-419.
19. Chamilos G, Lionakis MS, Lewis RE., et al. Drosophila melanogaster as a facile model for large-scale studies of virulence mechanisms and antifungal drug efficacy in Candida species. J Infect Dis. 2006; 193 (7): 1014-1022.
20. Lionakis MS, Lewis RE, May GS., et al. Toll-deficient Drosophila flies as a fast, high-throughput model for the study of antifungal drug efficacy against invasive aspergillosis and Aspergillus virulence. J Infect Dis. 2005; 191 (7): 1188-1195.
21. Aperis G, Mylonakis E. Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations. Expert Opin Investig Drugs. 2006; 15 (6): 579-602.
22. Irazoqui JE, Urbach JM, Ausubel FM. Evolution of host innate defence: insights from Caenorhabditis elegans and primitive invertebrates. Nat Rev Immunol. 2010; 10 (1): 47-58.
23. Consortium CeS. Genome sequence of the nematode C. Elegans: a platform for investigating biology. Science. 1998; 282 (5396): 2012-2018.
24. Chen N, Lawson D, Bradnam K., et al. WormBase as an integrated platform for the C. Elegans ORFeome. Genome Res. 2004; 14 (10B): 2155-2161.
25. Harris TW, Antoshechkin I, Bieri T., et al. WormBase: a comprehensive resource for nematode research. Nucleic Acids Res. 2010; 38 (Database issue): D463-7.
26. Mylonakis E, Ausubel FM, Tang RJ., et al. The art of serendipity: killing of Caenorhabditis elegans by human pathogens as a model of bacterial and fungal pathogenesis. Expert Rev Anti Infect Ther. 2003; 1 (1): 167-173.
27. Byerly L, Cassada RC, Russell RL. The life cycle of the nematode Caenorhabditis elegans. I. Wild-type growth and reproduction. Dev Biol. 1976; 51 (1): 23-33.
28. Aballay A, Ausubel FM. Caenorhabditis elegans as a host for the study of host-pathogen interactions. Curr Opin Microbiol. 2002; 5 (1): 97-101.
29. Avery L, Shtonda BB. Food transport in the C. Elegans pharynx. J Exp Biol. 2003; 206 (Pt 14): 2441-2457.
30. Glavis-Bloom J, Muhammed M, Mylonakis E. Of model hosts and man: using Caenorhabditis elegans, Drosophila melanogaster and Galleria mellonella as model hosts for infectious disease research. Adv Exp Med Biol. 2012; 710: 11-17.
31. Baldauf SL, Palmer JD. Animals and fungi are each others closest relatives: congruent evidence from multiple proteins. Proc Natl Acad Sci USA. 1993; 90 (24): 11558-11562.
32. Desalermos A, Tan X, Rajamuthiah R., et al. A multi-host approach for the systematic analysis of virulence factors in Cryptococcus neoformans. J Infect Dis. 2015; 211 (2): 298-305.
33. Garsin DA, Sifri CD, Mylonakis E., et al. A simple model host for identifying Gram-positive virulence factors. Proc Natl Acad Sci USA. 2001; 98 (19): 10892-10897.
34. London R, Orozco BS, Mylonakis E. The pursuit of cryptococcal pathogenesis: heterologous hosts and the study of cryptococcal host-pathogen interactions. FEMS Yeast Res. 2006; 6 (4): 567-573.
35. Pukkila-Worley R, Peleg AY, Tampakakis E., et al. Candida albicans hyphal formation and virulence assessed using a Caenorhabditis elegans infection model. Eukaryot Cell. 2009; 8 (11): 1750-1758.
36. Muhammed M, Fuchs BB, Wu MP., et al. The role of mycelium production and a MAPK-mediated immune response in the C. Elegans-Fusarium model system. Med Mycol. 2012; 50 (5): 488-496.
37. Kim DH, Feinbaum R, Alloing G., et al. A conserved p38 MAP kinase pathway in Caenorhabditis elegans innate immunity. Science. 2002; 297 (5581): 623-626.
38. Means TK, Mylonakis E, Tampakakis E., et al. Evolutionarily conserved recognition and innate immunity to fungal pathogens by the scavenger receptors SCARF1 and CD36. J Exp Med. 2009; 206 (3): 637-653.
39. Irazoqui JE, Ausubel FM. 99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: Caenorhabditis elegans as a model to study tissues involved in host immunity and microbial pathogenesis. Clin Exp Immunol. 2010; 160 (1): 48-57.
40. Breger J, Fuchs BB, Aperis G., et al. Antifungal chemical compounds identified using a C. Elegans pathogenicity assay. PLoS Pathog. 2007; 3 (2): e18.
41. Fuchs BB, Mylonakis E. Using non-mammalian hosts to study fungal virulence and host defense. Curr Opin Microbiol. 2006; 9 (4): 346-351.
42. Rajamuthiah R, Fuchs BB, Jayamani E., et al. Whole animal automated platform for drug discovery against multi-drug resistant Staphylococcus aureus. PLoS One. 2014; 9 (2): e89189.
43. Sifri CD, Begun J, Ausubel FM. The worm has turned-microbial virulence modeled in Caenorhabditis elegans. Trends Microbiol. 2005; 13 (3): 119-127.
44. Tan MW, Mahajan-Miklos S, Ausubel FM. Killing of Caenorhabditis elegans by Pseudomonas aeruginosa used to model mammalian bacterial pathogenesis. Proc Natl Acad Sci USA. 1999; 96 (2): 715-720.
45. Moy TI, Ball AR, Anklesaria Z., et al. Identification of novel antimicrobials using a live-animal infection model. Proc Natl Acad Sci USA. 2006; 103 (27): 10414-10419.
46. Desalermos A, Muhammed M, Glavis-Bloom J., et al. Using C. Elegans for antimicrobial drug discovery. Expert Opin Drug Discov. 2011; 6 (6): 645-652.
47. Tampakakis E, Okoli I, Mylonakis EA. C. Elegans-based, whole animal, in vivo screen for the identification of antifungal compounds. Nat Protoc. 2008; 3 (12): 1925-1931.
48. Anastassopoulou CG, Fuchs BB, Mylonakis E. Caenorhabditis elegans-based model systems for antifungal drug discovery. Curr Pharm Des. 2011; 17 (13): 1225-1233.
49. Muhammed M, Coleman JJ, Mylonakis E. Caenorhabditis elegans: a nematode infection model for pathogenic fungi. Methods Mol Biol. 2012; 845: 447-454.
50. Coleman JJ, Okoli I, Tegos GP., et al. Characterization of plant-derived saponin natural products against Candida albicans. ACS Chem Biol. 2010; 5 (3): 321-332.
51. Wahlby C, Kamentsky L, Liu ZH., et al. An image analysis toolbox for high-throughput C. Elegans assays. Nat Methods. 2012; 9 (7): 714-716.
52. Jospin M, Jacquemond V, Mariol MC., et al. The L-type voltage-dependent Ca2+ channel EGL-19 controls body wall muscle function in Caenorhabditis elegans. J Cell Biol. 2002; 159 (2): 337-348.
53. Kobet RA, Pan X, Zhang B., et al. Caenorhabditis elegans: a model system for anti-cancer drug discovery and therapeutic target identification. Biomol Ther (Seoul). 2014; 22 (5): 371-383.
54. Okoli I, Coleman JJ, Tampakakis E., et al. Identification of antifungal compounds active against Candida albicans using an improved high-throughput Caenorhabditis elegans assay. PLoS One. 2009; 4 (9): e7025.
55. Di Santo R. Natural products as antifungal agents against clinically relevant pathogens. Nat Prod Rep. 2010; 27 (7): 1084-1098.
56. Jiang Z, Liu N, Hu D., et al. The discovery of novel antifungal scaffolds by structural simplification of the natural product sampangine. Chem Commun (Camb). 2015; 51 (78): 14648-14651.
57. He X, Jiang Y, Zhang Y., et al. Discovery of highly potent triazoleantifungal agents with piperidine-oxadiazole side chains. Med Chem Commun. 2015; 6 (4): 653-664.
58. Liu Y, Wang Y, Dong G., et al. Novel benzothiazole derivatives with a broad antifungal spectrum: design, synthesis and structure-activity relationships. Med Chem Commun. 2013; 4 (12): 1551-1561.
59. Zhou YM, Shao L, Li JA., et al. An efficient and novel screening model for assessing the bioactivity of extracts against multidrug-resistant Pseudomonas aeruginosa using Caenorhabditis elegans. Biosci Biotechnol Biochem. 2011; 75 (9): 1746-1751.
60. Kino T, Hatanaka H, Miyata S., et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo). 1987; 40 (9): 1256-1265.
61. Kino T, Hatanaka H, Hashimoto M., et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo). 1987; 40 (9): 1249-1255.
62. Wenzel RP, Gennings C. Bloodstream infections due to Candida species in the intensive care unit: identifying especially high-risk patients to determine prevention strategies. Clin Infect Dis. 2005; 41 (Suppl 6): S389-93.
63. Pappas PG, Alexander BD, Andes DR., et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis. 2010; 50 (8): 1101-1111.
64. Pfaller MA, Lockhart SR, Pujol C., et al. Hospital specificity, region specificity, and fluconazole resistance of Candida albicans bloodstream isolates. J Clin Microbiol. 1998; 36 (6): 1518-1529.
65. Pfaller MA, Gerarden T. Susceptibility of clinical isolates of C andida spp. to terconazole and other azole antifungal agents. Diagn Microbiol Infect Dis. 1989; 12 (6): 467-471.
66. Pfaller MA, Jones RN, Messer SA., et al. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and control of pathogens of epidemiologic. Diagn Microbiol Infect Dis. 1998; 30 (2): 121-129.
67. Ostrosky-Zeichner L, Casadevall A, Galgiani JN., et al. An insight into the antifungal pipeline: selected new molecules and beyond. Nat Rev Drug Discov. 2010; 9 (9): 719-727.
68. Petrikkos G, Skiada A. Recent advances in antifungal chemotherapy. Int J Antimicrob Agents. 2007; 30 (2): 108-117.
69. Wang Y. Looking into Candida albicans infection, host response, and antifungal strategies. Virulence. 2015; 6 (4): 307-308.
70. Souza AC, Fuchs BB, Pinhati HM., et al. Candida parapsilosis resistance to fluconazole: molecular mechanisms and in vivo impact in infected Galleria mellonella larvae. Antimicrob Agents Chemother. 2015; 59 (10): 6581-6587.
71. Coleman JJ, Mylonakis E. Efflux in fungi: la piece de resistance. PLoS Pathog. 2009; 5 (6): e1000486.
72. Zhang SQ, Miao Q, Li LP., et al. Mutation of G234 amino acid residue in Candida albicans drug-resistance-related protein Rta2p is associated with fluconazole resistance and dihydrosphingosine transport. Virulence. 2015; 6 (6): 611-619.
73. Buckingham SD, Partridge FA, Sattelle DB. Automated, high-throughput, motility analysis in Caenorhabditis elegans and parasitic nematodes: applications in the search for new anthelmintics. Int J Parasitol Drugs Drug Resist. 2014; 4 (3): 226-232.
74. Burns AR, Kwok TC, Howard A., et al. High-throughput screening of small molecules for bioactivity and target identification in Caenorhabditis elegans. Nat Protoc. 2006; 1 (4): 1906-1914.
75. Macarron R, Hertzberg RP. Design and implementation of high throughput screening assays. Methods Mol Biol. 2002; 190: 1-29.
76. Macarron R, Hertzberg RP. Design and implementation of high-throughput screening assays. Methods Mol Biol. 2009; 565: 1-32.
77. Coleman JJ, Ghosh S, Okoli I., et al. Antifungal activity of microbial secondary metabolites. PLoS One. 2011; 6 (9): e25321.
78. Cole RD, Anderson GL, Williams PL. The nematode Caenorhabditis elegans as a model of organophosphate-induced mammalian neurotoxicity. Toxicol Appl Pharmacol. 2004; 194 (3): 248-256.
79. Cox GN, Kusch M, Edgar RS. Cuticle of Caenorhabditis elegans: its isolation and partial characterization. J Cell Biol. 1981; 90 (1): 7-17.
80. Schreiber SL, Kotz JD, Li M., et al. Advancing biological understanding and therapeutics discovery with small-molecule probes. Cell. 2015; 161 (6): 1252-1265.